As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers. The life ...

2024 marks the sixth consecutive year production guidance has been achieved Toronto, Ontario--(Newsfile Corp. - January 8, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.

In a report released today, Luke Sergott from Barclays maintained a Buy rating on 10x Genomics (TXG – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $8.67.

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties 10x Genomics reported a Q4 EPS loss of $(0.40), missing estimates ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers.

Torex Gold Resources Inc. operates as an intermediate gold producer. The company engages in the exploration, development, and operation of principal asset comprising 100% owned the Morelos Gold ...